Sompraz%25252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252520hp

# Sompraz HP (Pantoprazole) ## Overview Pantoprazole is a proton pump inhibitor (PPI) that reduces gastric acid production. Sompraz HP is a brand name for pantoprazole. ## Primary Indications * Gastroesophageal reflux disease (GERD) * Erosive esophagitis healing and maintenance * Zollinger-Ellison syndrome and other hypersecretory conditions * Part of *Helicobacter pylori* eradication regimens ## Adult Dosing * **GERD/Erosive Esophagitis Healing:** 40 mg orally or intravenously once daily for up to 8 weeks. * **GERD Maintenance:** 20 mg to 40 mg orally once daily. * **Hypersecretory Conditions:** 40 mg orally or intravenously every 12 hours. Doses may be increased to 80 mg intravenously every 12 hours or 160 mg intravenously every 24 hours, followed by adjustment based on gastric acid output. * ***H. pylori* Eradication (in combination):** 40 mg orally twice daily for 7 to 14 days, in conjunction with antibiotics (e.g., amoxicillin and clarithromycin, or metronidazole and clarithromycin). ## Pediatric Dosing * **GERD (Oral):** * 1 to 5 years (15 kg to <40 kg): 10 mg orally once daily. * 5 to 12 years (<40 kg): 20 mg orally once daily. * 5 to 12 years (≥40 kg): 40 mg orally once daily. * 12 years and older: 40 mg orally once daily. * Dosing for >12 years should be a maximum of 40 mg once daily unless treating erosive esophagitis (up to 8 weeks). * **Erosive Esophagitis (Oral):** * 5 to 12 years (<40 kg): 20 mg orally once daily for up to 8 weeks. * 5 to 12 years (≥40 kg): 40 mg orally once daily for up to 8 weeks. * 12 years and older: 40 mg orally once daily for up to 8 weeks. * **Intravenous Dosing (Pediatric):** Data is limited. Consult specific institutional protocols or specialized literature for intravenous use in children. ## Dose Adjustments * **Hepatic Impairment:** Maximum daily dose of 20 mg orally or 40 mg intravenously. * **Renal Impairment:** No dose adjustment necessary. ## Contraindications * Known hypersensitivity to pantoprazole, any component of the formulation, or other PPIs. ## Adverse Effects * **Common:** Diarrhea, headache, dizziness, abdominal pain, nausea, flatulence. * **Serious:** * Long-term use associated with increased risk of *Clostridium difficile*-associated diarrhea, bone fractures (hip, wrist, spine), hypomagnesemia, vitamin B12 deficiency, and potentially an increased risk of gastric polyps (fundic gland polyps). * Acute interstitial nephritis. * Cutaneous and systemic lupus erythematosus. ## Key Drug Interactions * **Drugs requiring gastric acid for absorption:** PPIs can decrease absorption of drugs like ketoconazole, itraconazole, posaconazole, iron salts, and certain HIV protease inhibitors (e.g., atazanavir, nelfinavir). * **Methotrexate:** PPIs may increase methotrexate levels. * **CYP2C19 Substrates:** Pantoprazole is a moderate inhibitor of CYP2C19. Consider potential interactions with drugs like clopidogrel (though clinical significance is debated), citalopram, and others metabolized by this enzyme. * **Sucralfate:** May decrease absorption of pantoprazole. Administer pantoprazole at least 30 minutes before sucralfate. ## Monitoring * Electrolytes (especially magnesium) with prolonged therapy. * Bone mineral density if risk factors for osteoporosis are present. * Signs and symptoms of *C. difficile* infection. * Vitamin B12 levels with very long-term therapy (>3 years). * Renal function if acute interstitial nephritis is suspected. ## Clinical Pearls * Pantoprazole is generally dosed once daily, but for hypersecretory conditions or *H. pylori* eradication, twice-daily dosing is used. * For IV administration, reconstitute lyophilized powder with sterile water for injection and further dilute with a compatible IV fluid (e.g., 0.9% Sodium Chloride or 5% Dextrose). * PPIs should be used at the lowest effective dose for the shortest duration necessary to treat the condition. * Administer oral pantoprazole delayed-release tablets at least 1 hour before a meal. * Ensure patients are aware of potential long-term risks associated with PPI therapy. *** **Disclaimer:** This information is intended for healthcare professionals. It is essential to consult the most current prescribing information and relevant clinical guidelines for definitive patient management. Dosing and recommendations may vary based on local protocols and individual patient factors.